Screener
Relay Therapeutics, Inc. RLAY Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $350K-48.3% | $3M-60.9% | $7M— | $0— | $677K— | ||
| $76.48M+19.7% | $70.56M-4.4% | $55.42M-18.6% | $68.26M-10.9% | $63.9M-30.5% | ||
| $14.69M+7.8% | $11.03M-41.2% | $12.22M-27.7% | $12.13M-38.6% | $13.63M-32.3% | ||
| $91.17M+17.6% | $81.59M-11.8% | $67.63M-20.4% | $80.39M-16.6% | $77.52M-23.1% | ||
| -$90.82M-18.2% | -$78.59M+7.4% | -$60.63M+28.7% | -$80.39M+16.6% | -$76.85M+23.7% | ||
| -25,949.7%-14,599pp | -2,619.7%-1,514pp | -866.1%— | —— | -11,351.1%— | ||
| $7.12M+10.0% | $5.3M-32.1% | $5.74M-36.0% | $6.24M-24.5% | $6.47M-24.3% | ||
| -$83.71M-18.9% | -$73.29M+4.9% | -$54.89M+27.8% | -$74.15M+15.8% | -$70.38M+23.7% | ||
| -23,916.3%-13,521pp | -2,443%-1,439pp | -784.1%— | —— | -10,395.1%— | ||
| -$0.410.0% | -$0.41+10.9% | -$0.31+26.2% | -$0.43+31.7% | -$0.41+40.6% | ||
| -$90.46M-19.3% | -$78.09M+6.7% | -$60.03M+28.2% | -$79.64M+16.2% | -$75.85M+23.7% | ||
| -25,846.9%-14,644pp | -2,602.9%-1,513pp | -857.6%— | —— | -11,203.1%— | ||
| -$90.82M-18.2% | -$78.59M+7.4% | -$60.63M+28.7% | -$80.39M+16.6% | -$76.85M+23.7% |
FAQ
- What is Relay Therapeutics, Inc.'s revenue?
- Relay Therapeutics, Inc. (RLAY) generated $10.4M in revenue over the trailing twelve months, up 23.9% year over year.
- Is Relay Therapeutics, Inc. profitable?
- Relay Therapeutics, Inc. is not currently profitable: it reported a net loss of $286.0M over the trailing twelve months, a -2763.6% net margin.
- What is Relay Therapeutics, Inc.'s earnings per share?
- Relay Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-1.56.
- Where does Relay Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Relay Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
